Thus, the ready availability of Nefiracetam and PHA 543613 and their capacity to specifically improve the neurocytopathology identified in our human MECP2‐KO models encourages suggestion of clinical efficacy and therapeutic trial for patients with neurodevelopmental disorders. Here, MECP2 is linked to neurodevelopmental disorder.